A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease

A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease

Abstract Antibody‐mediated removal of aggregated β‐amyloid (Aβ) is the current, most clinically advanced potential disease‐modifying treatment approach for Alzheimer's disease. We describe a quantitative systems pharmacology (QSP) approach of the dynamics of Aβ monomers, oligomers, protofibrils...

Full description

Bibliographic Details
Main Authors:	Hugo Geerts, Mike Walker, Rachel Rose, Silke Bergeler, Piet H. van derGraaf, Edgar Schuck, Akihiko Koyama, Sanae Yasuda, Ziad Hussein, Larisa Reyderman, Chad Swanson, Antonio Cabal
Format:	Article
Language:	English
Published:	Wiley 2023-04-01
Series:	CPT: Pharmacometrics & Systems Pharmacology
Online Access:	https://doi.org/10.1002/psp4.12912

Similar Items

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease
by: Seiichi Hayato, et al.
Published: (2022-12-01)

Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model
by: Hugo Geerts, et al.
Published: (2023-09-01)

Salvaging CNS Clinical Trials Halted Due to COVID‐19
by: Hugo Geerts, et al.
Published: (2020-07-01)

Pharmacometrics and/or Systems Pharmacology
by: Piet H. van derGraaf
Published: (2019-06-01)

A modeling informed quantitative approach to salvage clinical trials interrupted due to COVID‐19
by: Hugo Geerts, et al.
Published: (2020-01-01)

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
by: Satish Dayal, et al.
Published: (2021-04-01)

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
by: Ishani Landry, et al.
Published: (2021-04-01)

Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges
by: Hugo Geerts, et al.
Published: (2020-01-01)

Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
by: Eric McDade, et al.
Published: (2022-12-01)

QSP Designer: Quantitative systems pharmacology modeling with modular biological process map notation and multiple language code generation
by: Richard J. Matthews, et al.
Published: (2023-07-01)

Regulation of Pom cluster dynamics in Myxococcus xanthus.
by: Silke Bergeler, et al.
Published: (2018-08-01)

Learn–confirm in model‐informed drug development: Assessing an immunogenicity quantitative systems pharmacology platform
by: Linnea C. Franssen, et al.
Published: (2023-02-01)

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
by: Lawrence S. Honig, et al.
Published: (2023-01-01)

Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model
by: Hugo Geerts, et al.
Published: (2018-02-01)

Amyloid precursor proteins are protective in Drosophila models of progressive neurodegeneration
by: Jill S. Wentzell, et al.
Published: (2012-04-01)

Modeling amyloids in bacteria
by: Villar-Piqué Anna, et al.
Published: (2012-12-01)

Utility of Three-Dimensional Cultures of Primary Human Hepatocytes (Spheroids) as Pharmacokinetic Models
by: Kenta Mizoi, et al.
Published: (2020-09-01)

Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
by: Chad J. Swanson, et al.
Published: (2022-05-01)

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
by: Chad J. Swanson, et al.
Published: (2021-04-01)

Evaluation of pharmacokinetics of warfarin from validated pharmacokinetic-pharmacodynamic model
by: Kannan Sridharan, et al.
Published: (2021-01-01)

Pharmacokinetic-pharmacodynamic modeling and simulation /
by: 192959 Bonate, Peter L.
Published: (2005)

Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy
by: Kazuto Yamashita, et al.
Published: (2022-06-01)

Deep learning quantification of vascular pharmacokinetic parameters in mouse brain tumor models
by: Chad A. Arledge, et al.
Published: (2022-03-01)

Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats
by: Yoo-Kyung Song, et al.
Published: (2021-03-01)

The effect of azithromycin on ivermectin pharmacokinetics--a population pharmacokinetic model analysis.
by: Ahmed El-Tahtawy, et al.
Published: (2008-01-01)

Unravelling bisphenol A pharmacokinetics using physiologically based pharmacokinetic modeling
by: Xiaoxia eYang, et al.
Published: (2015-01-01)

MODELIZATION OF AMYLOID FIBRIL SELF-ASSEMBLY
by: V. Trusova, et al.
Published: (2018-04-01)

Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model
by: Yuan Chen, et al.
Published: (2019-09-01)

A novel cardiovascular systems model to quantify drugs effects on the inter‐relationship between contractility and other hemodynamic variables
by: Yu Fu, et al.
Published: (2022-05-01)

Model‐informed target identification and validation through combining quantitative systems pharmacology with network‐based analysis
by: Vijayalakshmi Chelliah, et al.
Published: (2022-04-01)

PomX, a ParA/MinD ATPase activating protein, is a triple regulator of cell division in Myxococcus xanthus
by: Dominik Schumacher, et al.
Published: (2021-03-01)

Utilization of Physiologically Based Pharmacokinetic Modeling in Pharmacokinetic Study of Natural Medicine: An Overview
by: Qiuyu Jia, et al.
Published: (2022-12-01)

Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design.
by: Micaela B Reddy, et al.
Published: (2015-01-01)

Reference physiological parameters in pharmacokinetic modeling /
by: 268339 Arms, Angela D., et al.
Published: (1988)

One-compartment stochastic pharmacokinetic model
by: Ricardo Cano Macías, et al.
Published: (2023-03-01)

Multiphysics pharmacokinetic model for targeted nanoparticles
by: Emma M. Glass, et al.
Published: (2022-07-01)

A Stochastic Model for the Ethanol Pharmacokinetics
by: Mazyar GHADIRINEJAD, et al.
Published: (2016-10-01)

The Role of Basement Membranes in Cerebral Amyloid Angiopathy
by: Matthew D. Howe, et al.
Published: (2020-11-01)

Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease
by: Kenta Yoshida, et al.
Published: (2020-01-01)

Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease
by: Kumar Kandadi Muralidharan, et al.
Published: (2022-01-01)